NCT05274633View on ClinicalTrials.gov

Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

March 24, 2025

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Ravulizumab

Participants will be observed for 52 weeks after the start of ravulizumab.

Trial Locations (6)

Unknown

Clinical Trial Site, Brescia

Clinical Trial Site, Catania

Clinical Trial Site, Lecce

Clinical Trial Site, Ragusa

Clinical Trial Site, Roma

Clinical Trial Site, Salerno

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY